New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Actuate Therapeutics, Inc. (ACTU) vs Bolt Biotherapeutics, Inc. (BOLT)

Actuate Therapeutics, Inc. and Bolt Biotherapeutics, Inc. are both Biotechnology companies. Actuate Therapeutics, Inc. and Bolt Biotherapeutics, Inc. are of similar size ($13.2M and $12.9M). Across the 9 metrics below, Bolt Biotherapeutics, Inc. leads on 6 and Actuate Therapeutics, Inc. on 3.

Valuation

Metric ACTU BOLT Biotechnology median
P/E n/m n/m 8.49
P/S — 2.07 8.56
P/B n/m 1.14 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales — 2.64 8.00
Earnings yield (346.00%) (301.80%) (35.81%)
Free cash flow yield (302.29%) (247.02%) (25.41%)

Profitability

Metric ACTU BOLT Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin — (654.53%) 0.00%
Net margin — (611.47%) 0.00%
Free cash flow margin — (655.72%) 0.00%
Return on equity (364.70%) (127.96%) (51.58%)
Return on assets (176.44%) (51.70%) (45.91%)
Return on invested capital 0.00% (154.77%) 0.00%

Growth

Metric ACTU BOLT Biotechnology median
Revenue growth (TTM) — 12.79% 7.20%
EPS growth (last fiscal year) 67.48% 45.91% 29.04%
Revenue growth, 5-year CAGR — 101.61% 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ACTU BOLT Biotechnology median
Debt to equity 0.00 2.06 0.00
Current ratio 0.73 2.05 4.79
Net debt to EBITDA 0.59 0.21 1.01

Dividend

Metric ACTU BOLT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACTU BOLT Biotechnology median
Market cap 12.91m 13.20m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack